Phase 3 Completed N=83 Randomized Quadruple-blind Treatment

Pentoxifylline Treatment in Acute Pancreatitis (AP)

Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis · Trauma Acute Pancreatitis

Source: ClinicalTrials.gov NCT02487225 ↗

Enrolled (actual)

Serious AEs

1.2%

Results posted

Jan 2019

Primary outcomePrimary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.	86.2; 75.8; 116.4; 127.2	0.5796
PRIMARY Change in Tumor Necrosis Factor-alpha (TNF-a) Levels From Admission Baseline at One Week.	1.9; 1.8; 4.3; 1.9	0.1109
PRIMARY Change in Interleukin-6 (IL-6) Levels From Admission Baseline at One Week.	107.9; 89.1; 81.8; 88.6	0.1236
PRIMARY Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.	43.7; 31.5; 45.9; 32.1	0.157

Eligibility Criteria

Inclusion criteria

Enrollment within 72 hours of diagnosis of acute pancreatitis (AP)
Ability to give informed consent or a Legal Adult Representative (LAR) able to give informed consent for subject when needed as defined buy LAR use guidelines.
Adult subjects of age ≥18 years.

Exclusion Criteria

Moderate or severe congestive heart failure
History of seizure disorders or demyelinating disease
Nursing mothers
Pregnancy
History of prior tuberculosis or risk factors for tuberculosis
Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal failure, chemotherapy within 60 days, and HIV)
Evidence of active hemorrhage
Paralytic ileus with severe nausea and vomiting

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02487225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.